ELIMINATION OF EGFR-OVEREXPRESSING CANCER CELLS BY CD32 CHIMERIC RECEPTOR T CELLS IN COMBINATION WITH CETUXIMAB OR PANITUMUMAB
S. Caratelli, R. Arriga, T. Sconocchia, A. Ottaviani, G. Lanzilli, D. Pastore, C. Cenciarelli, A. Venditti, M. I. Del Principe, D. Lauro, E. Landoni, H. Du, B. Savoldo, S. Ferrone, G. Dotti, G. Sconocchia
This study shows CD32131R-CR T cells can eliminate EGFR-overexpressing cancer cells when combined with cetuximab or panitumumab, outperforming CD16158F-CR T cells.
bioRxiv · Mar 18, 2019 · PreprintImmunology